TP53 and B-cell chronic lymphocytic leukemia: Current National Comprehensive Cancer Network and the European Society for Medical Oncology practice guidelines recommend that first-line treatment for patients with CLL should be based on the presence or absence of del(17p) or mutated TP53, regardless of patient age and comorbidities (39, 58), and preference should be given to small molecules.